A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | - | - |
| Net Income | -1.1B | -1.1B | -600M | -436M | -249M | -187M |
| EPS | $-5.95 | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 |
| Free Cash Flow | -914M | -914M | -568M | -358M | -235M | -154M |
| ROIC | -66.4% | -58.1% | -26.5% | -23.9% | -36.3% | -31.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.10 | 0.10 | 0.06 | 0.05 | 0.18 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -1.2B | -1.2B | -690M | -487M | -258M | -188M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -69.3% | -58.1% | -26.5% | -23.9% | -36.3% | -31.0% |
| Shares Outstanding | 190M | 190M | 168M | 113M | 165M | 73M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | 50M | N/A | N/A | N/A | N/A | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 51M | 92M | 132M | 187M | 253M | 423M | 592M | 987M | 987M |
| SG&A | 9.4M | 12M | 21M | 30M | 41M | 76M | 97M | 195M | 195M |
| EBIT | -40M | -54M | -111M | -188M | -258M | -487M | -690M | -1.2B | -1.2B |
| Op. Margin | N/A | -108.2% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -49M | -62M | -110M | -187M | -249M | -436M | -600M | -1.1B | -1.1B |
| Net Margin | N/A | -123.7% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 1.2M | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | N/M | -24.5% | -23.3% | -31.0% | -36.3% | -23.9% | -26.5% | -58.1% | -66.4% |
| ROE | N/A | N/A | -23.3% | -31.0% | -36.3% | -23.9% | -26.5% | -58.1% | -69.3% |
| ROA | -5370.7% | -28.1% | -19.5% | -25.4% | -30.6% | -21.2% | -23.5% | -46.1% | -48.0% |
| Cash Flow | |||||||||
| Op. Cash Flow | 1.2M | -50M | -100M | -147M | -224M | -351M | -557M | -898M | -898M |
| Free Cash Flow | -286K | -52M | -103M | -154M | -235M | -358M | -568M | -914M | -914M |
| Owner Earnings | -1.2M | -55M | -112M | -171M | -261M | -417M | -643M | -1.0B | -1.0B |
| CapEx | 1.5M | 2.6M | 2.9M | 6.5M | 11M | 7.7M | 10M | 16M | 16M |
| Maint. CapEx | 1.6M | 2.3M | 2.6M | 3.1M | 5.0M | 5.0M | 6.6M | 7.8M | 7.8M |
| Growth CapEx | 0 | 316K | 322K | 3.4M | 5.8M | 2.7M | 3.7M | 8.2M | 8.2M |
| D&A | 1.6M | 2.3M | 2.6M | 3.1M | 5.0M | 5.0M | 6.6M | 7.8M | 7.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 855K | 3.2M | 8.9M | 21M | 31M | 62M | 79M | 118M | 118M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | N/A | -408M | -510M | N/A | -1.8B | -2.2B | -1.9B | -225M |
| Cash & Equiv. | 70M | 17M | 104M | 108M | 161M | 696M | 543M | 384M | 384M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 159M |
| Debt/Equity | -1.01 | -0.45 | 0.07 | 0.11 | 0.18 | 0.05 | 0.06 | 0.10 | 0.10 |
| Interest Coverage | -347.7 | -510.6 | -1559.1 | -15667.3 | N/A | N/A | N/A | -48.8 | -48.8 |
| Equity | -108M | -153M | 475M | 603M | 685M | 1.8B | 2.3B | 1.6B | 1.6B |
| Total Assets | 909K | 221M | 567M | 738M | 812M | 2.1B | 2.6B | 2.4B | 2.4B |
| Total Liabilities | 109M | 68M | 93M | 135M | 127M | 236M | 293M | 723M | 723M |
| Intangibles | N/A | 62M | 61M | 60M | 59M | 58M | 57M | 56M | 56M |
| Retained Earnings | N/A | -157M | -266M | -453M | -701M | -1.1B | -1.7B | -2.9B | -2.9B |
| Working Capital | N/A | 91M | 407M | 529M | 598M | 1.7B | 2.2B | 1.8B | 1.8B |
| Current Assets | N/A | 134M | 454M | 590M | 660M | 1.9B | 2.3B | 2.1B | 2.1B |
| Current Liabilities | 311K | 43M | 47M | 60M | 62M | 144M | 164M | 290M | 290M |
| Per Share Data | |||||||||
| EPS | -21.24 | -22.33 | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 | -5.95 |
| Owner EPS | -0.53 | -0.75 | -2.03 | -2.35 | -1.58 | -3.69 | -3.84 | -5.39 | -5.39 |
| Book Value | -47.17 | -2.08 | 8.64 | 8.28 | 4.16 | 16.15 | 13.51 | 8.58 | 8.58 |
| Cash Flow/Share | 0.53 | -0.68 | -1.82 | -2.02 | -1.36 | -3.10 | -3.33 | -4.72 | -5.91 |
| Dividends/Share | N/A | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.3M | 73.4M | 54.9M | 72.8M | 164.7M | 113.0M | 167.6M | 190.1M | 190.1M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -22.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 4.7 | 3.1 | 5.4 | 1.8 | 3.3 | 9.4 | 15.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -4.6% | -8.1% | -6.4% | -10.8% | -7.7% | -6.0% | -3.5% |
| Market Cap | N/A | N/A | 2.3B | 1.9B | 3.7B | 3.3B | 7.4B | 15.4B | 25.9B |
| Avg. Price | N/A | N/A | 32.02 | 34.33 | 21.17 | 25.68 | 40.32 | 45.65 | 136.30 |
| Year-End Price | N/A | N/A | 41.04 | 25.99 | 22.32 | 29.37 | 44.21 | 80.75 | 136.30 |
Revolution Medicines, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Revolution Medicines, Inc. (RVMD) has a 5-year average return on invested capital (ROIC) of -35.2%. This is below average and may indicate limited pricing power.
Revolution Medicines, Inc. (RVMD) has a market capitalization of $25.9B. It is classified as a large-cap stock.
Revolution Medicines, Inc. (RVMD) does not currently pay a regular dividend.
Revolution Medicines, Inc. (RVMD) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Revolution Medicines, Inc. (RVMD) generated $-914 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Revolution Medicines, Inc. (RVMD) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
Revolution Medicines, Inc. (RVMD) reported earnings per share (EPS) of $-5.95 in its most recent fiscal year.
Revolution Medicines, Inc. (RVMD) has a return on equity (ROE) of -58.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for Revolution Medicines, Inc. (RVMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Revolution Medicines, Inc. (RVMD) has a book value per share of $8.58, based on its most recent annual SEC filing.